MSMarina Spanos

Marina Spanos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marina Spanos has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Digital Phenotyping based on a Mobile App Identifies Distinct and Overlapping Features in Children Diagnosed with Autism versus ADHD

    by Vikram Aikat, Pradeep Raj Krishnappa Babu, Kimberly L.H. Carpenter, J. Matias Di Martino, Steven Espinosa, Naomi Davis, Lauren Franz, Marina Spanos, Geraldine Dawson, Guillermo Sapiro

    The high prevalence of autism calls for accessible and scalable technology-assisted screening tools. This will aid in early detection allowing timely access to services and supports. SenseToKnow, a mobile digital phenotyping app, showed potential in eliciting autism-related behaviors that can be automatically captured via computer vision analysis (CVA) in toddlers. Here, we present the capability of SenseToKnow in characterizing autism in school age children and showcase the robustness of the CVA features in interpreting distinct and overlapping behaviors with attention-deficit/hyperactive disorder (ADHD).


  • Validation of a Mobile App for Remote Autism Screening in Toddlers

    by Pradeep Raj Krishnappa Babu, J. Matias Di Martino, Rachel Aiello, Brian Eichner, Steven Espinosa, Jennifer Green, Jill Howard, Sam Perochon, Marina Spanos, Saritha Vermeer, et al.

    Early detection of autism is important for timely access to diagnostic evaluation and early intervention services, which improve children's outcomes. Despite the ability of clinicians to reliably diagnose autism in toddlers, diagnosis is often delayed. SenseToKnow is a mobile autism screening application (app) delivered on a smartphone or tablet that provides an objective and quantitative assessment of early behavioral signs of autism based on computer vision (CV) and machine learning (ML). This study examined the accuracy of SenseToKnow for autism detection when the app was downloaded and administered remotely at home by caregivers using their own devices. The SenseToKnow app was administered by caregivers of 620 toddlers between 16 and 40 months of age, 188 of whom were subsequently diagnosed with autism by expert clinicians. The app displayed strategically designed movies and a bubble-popping game on an iPhone or iPad while recording the child's behavioral responses through the device's front-facing camera and touch/inertial sensors. Recordings of the child's behavior were then automatically analyzed using CV. Multiple behavioral phenotypes were quantified and combined using ML in an algorithm for autism prediction. SenseToKnow demonstrated a high level of diagnostic accuracy with area under the receiver operating characteristic curve of 0.92, sensitivity of 83.0%, specificity of 93.3%, positive predictive value of 84.3%, and negative predictive value of 92.6%. Accuracy of the app for detecting autism was similar when administered on either a caregiver's iPhone or iPad. These results demonstrate that a mobile autism screening app based on CV can be delivered remotely by caregivers at home on their own devices and can provide a high level of accuracy for autism detection. Remote screening for autism potentially lowers barriers to autism screening, which could reduce disparities in early access to services and support and improve children's outcomes.


  • Brief Report: Relationships Between Caregiver-Reported Externalizing and Internalizing Behaviors and the Modified Checklist for Autism in Toddlers

    by Jane Marryat, Naomi O. Davis, Reginald Lerebours, Kimberly L. H. Carpenter, Scott Compton, Brian Eichner, Lauren Franz, Scott H. Kollins, Marina Spanos, Geraldine Dawson

    Purpose Early detection and intervention are associated with improved outcomes for autistic children. Thus, it is important to understand factors influencing early screening tools designed to detect autism. This study examined the relationship between caregiver-reported emotional and behavioral symptoms and children’s scores on a commonly used autism screening questionnaire, the Modified Checklist for Autism in Toddlers-Revised with Follow-Up (M-CHAT-R/F). Methods Toddlers were recruited from four primary care clinics between 2018 and 2021. Their caregivers completed the M-CHAT-R/F as well as the Child Behavior Checklist (CBCL), a well-validated, normed measure of emotional and behavioral functioning. Correlational and group analyses were evaluated to examine relationships between CBCL scales and M-CHAT-R/F scores. Results 1765 toddlers were recruited for the study. CBCL scores for the internalizing, externalizing, autism, ADHD, and anxiety scales were all modestly positively correlated with M-CHAT-R/F scores. Compared to toddlers with elevated autism scale scores only, toddlers with elevations in both autism and ADHD/externalizing scales had higher M-CHAT-R/F scores. In contrast, no significant difference in scores were found between toddlers with elevated autism scale scores only compared to those with elevated scores on both autism and internalizing scales. Conclusion Findings suggest that, for children with elevated autism behaviors, the presence of externalizing symptoms, including ADHD-related concerns, is associated with elevated scores on the M-CHAT-R/F. In contrast, internalizing symptoms did not show an association with elevated M-CHAT-R/F scores among toddlers with elevated autism-related behaviors. Interpretation of the M-CHAT-R/F should include consideration of co-occurring psychiatric conditions, especially externalizing conditions such as ADHD.

  • Open Access

    Genetic and epigenetic signatures associated with plasma oxytocin levels in children and adolescents with autism spectrum disorder

    by Stephen K. Siecinski, Stephanie N. Giamberardino, Marina Spanos, Annalise C. Hauser, Jason R. Gibson, Tara Chandrasekhar, Maria del Pilar Trelles, Carol M. Rockhill, Michelle L. Palumbo, Allyson Witters Cundiff, et al.

    Oxytocin (OT), the brain's most abundant neuropeptide, plays an important role in social salience and motivation. Clinical trials of the efficacy of OT in autism spectrum disorder (ASD) have reported mixed results due in part to ASD's complex etiology. We investigated whether genetic and epigenetic variation contribute to variable endogenous OT levels that modulate sensitivity to OT therapy. To carry out this analysis, we integrated genome‐wide profiles of DNA‐methylation, transcriptional activity, and genetic variation with plasma OT levels in 290 participants with ASD enrolled in a randomized controlled trial of OT. Our analysis identified genetic variants with novel association with plasma OT, several of which reside in known ASD risk genes. We also show subtle but statistically significant association of plasma OT levels with peripheral transcriptional activity and DNA‐methylation profiles across several annotated gene sets. These findings broaden our understanding of the effects of the peripheral oxytocin system and provide novel genetic candidates for future studies to decode the complex etiology of ASD and its interaction with OT signaling and OT‐based interventions.Lay Summary: Oxytocin (OT) is an abundant chemical produced by neurons that plays an important role in social interaction and motivation. We investigated whether genetic and epigenetic factors contribute to variable OT levels in the blood. To this, we integrated genetic, gene expression, and non‐DNA regulated (epigenetic) signatures with blood OT levels in 290 participants with autism enrolled in an OT clinical trial. We identified genetic association with plasma OT, several of which reside in known autism risk genes. We also show statistically significant association of plasma OT levels with gene expression and epigenetic across several gene pathways. These findings broaden our understanding of the factors that influence OT levels in the blood for future studies to decode the complex presentation of autism and its interaction with OT and OT‐based treatment.


  • 6.14 Randomized, Placebo-Controlled Trial With Open-Label Extension of Intranasal Oxytocin for Autism Spectrum Disorder

    by Marina Spanos, Terrence Bethea, Cheryl Alderman, Jacqueline Johnson, Tara Chandrasekhar, Linmarie Sikich